158 related articles for article (PubMed ID: 35922953)
1. [Treatment strategy for B cell precursor acute lymphoblastic leukemia in children].
Koh K
Rinsho Ketsueki; 2022; 63(7):816-825. PubMed ID: 35922953
[TBL] [Abstract][Full Text] [Related]
2. Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment.
Hu G; Cheng Y; Zuo Y; Chang Y; Suo P; Jia Y; Lu A; Wang Y; Jiao S; Zhang L; Sun Y; Yan C; Xu L; Zhang X; Liu K; Wang Y; Zhang L; Huang X
Front Immunol; 2022; 13():915590. PubMed ID: 35734165
[TBL] [Abstract][Full Text] [Related]
3. Recent progress in pediatric lymphoblastic leukemia.
Kato M
Int J Hematol; 2023 Feb; 117(2):155-161. PubMed ID: 36456860
[TBL] [Abstract][Full Text] [Related]
4. [Pediatric acute lymphoblastic leukemia: update on pathophysiology and management].
Kato M
Rinsho Ketsueki; 2018; 59(5):504-510. PubMed ID: 29877240
[TBL] [Abstract][Full Text] [Related]
5. Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group.
Escherich G; Zur Stadt U; Borkhardt A; Dilloo D; Faber J; Feuchtinger T; Imschweiler T; Jorch N; Pekrun A; Schmid I; Schramm F; Spohn M; Zimmermann M; Horstmann MA
Haematologica; 2022 May; 107(5):1026-1033. PubMed ID: 34348455
[TBL] [Abstract][Full Text] [Related]
6. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
7. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
[TBL] [Abstract][Full Text] [Related]
8. Clinicians' Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study.
Gidman W; Shah S; Zhang L; McKendrick J; Cong Z; Cohan D; Ottmann O
Adv Ther; 2019 Nov; 36(11):3017-3029. PubMed ID: 31586302
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
Verbeek MWC; Buracchi C; Laqua A; Nierkens S; Sedek L; Flores-Montero J; Hofmans M; Sobral de Costa E; Nováková M; Mejstrikova E; Barrena S; Kohlscheen S; Szczepanowski M; Kulis J; Oliveira E; Jugooa R; de Jong AX; Szczepanski T; Philippé J; van Dongen JJM; Orfao A; Brüggemann M; Gaipa G; van der Velden VHJ
Br J Haematol; 2022 Apr; 197(1):76-81. PubMed ID: 34881427
[TBL] [Abstract][Full Text] [Related]
10. The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia.
Xue YJ; Wang Y; Jia YP; Zuo YX; Wu J; Lu AD; Zhang LP
Int J Hematol; 2021 Apr; 113(4):547-555. PubMed ID: 33386596
[TBL] [Abstract][Full Text] [Related]
11. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease surveillance at day 90 predicts long-term survival in pediatric patients with T-cell acute lymphoblastic leukemia.
Liu X; Zou Y; Chen X; Wang S; Guo Y; Yang W; Zhang L; Chen Y; Zhang Y; Zhu X
Leuk Lymphoma; 2020 Dec; 61(14):3460-3467. PubMed ID: 32779947
[TBL] [Abstract][Full Text] [Related]
14. [Clinical Significance of Minimal Residual Disease in Risk Stratification and Prognosis of Childhood B-lineage Acute Lymphoblastic Leukemia].
An FY; Zhang SH; Kong LJ; Liang Y; Xu JX; He HL; Chai YH; Zhao WL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):729-735. PubMed ID: 28641626
[TBL] [Abstract][Full Text] [Related]
15. A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia.
Capria S; Molica M; Mohamed S; Bianchi S; Moleti ML; Trisolini SM; Chiaretti S; Testi AM
Expert Rev Hematol; 2020 Jul; 13(7):755-769. PubMed ID: 32419532
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
17. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
18. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
19. Childhood and adolescent lymphoid and myeloid leukemia.
Pui CH; Schrappe M; Ribeiro RC; Niemeyer CM
Hematology Am Soc Hematol Educ Program; 2004; ():118-45. PubMed ID: 15561680
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
Mussolin L; Pillon M; Conter V; Piglione M; Lo Nigro L; Pierani P; Micalizzi C; Buffardi S; Basso G; Zanesco L; Rosolen A
J Clin Oncol; 2007 Nov; 25(33):5254-61. PubMed ID: 18024872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
